The Completely Endoscopic Treatment of Atrial Fibrillation: Report on the First 14 Patients with Early Results
We report the early results of a new completely endoscopic technique for the treatment of atrial fibrillation (AF).
Methods: Fourteen patients underwent surgery solely for the treatment of AF. The thoracoscopic technique delivered microwave energy to the epicardial surface of the beating heart. Access was obtained through 3 right-sided and 3 left-sided thoracic ports. The AFx/Guidant Flex-10 catheter was employed to produce a box lesion around the pulmonary veins along with additional right- and left-sided lesions. The left atrial appendage was amputated.
Results: Ten patients had paroxysmal fibrillation, 1 had persistent fibrillation, and 3 were in permanent AF. Mean age of the group was 60 years, and their mean duration of AF was 74 months. Half had undergone unsuccessful attempts at chemical and/or electrical cardioversion. There were no deaths. Two patients required conversion to open procedure to control bleeding from the left atrial appendage. Average procedure time was 221 minutes, with the last 2 procedures taking less than 2 hours. Median length of hospital stay was 6 days, with 7 patients staying less than 3 days. Seventy-one percent of patients were in sinus rhythm at discharge, 100% at 6 months follow-up, and 67% at 12 months.
Conclusion: Totally endoscopic microwave ablation of atrial fibrillation appears to be safe and truly minimally invasive. It is associated with a short length of stay, short procedure time, and acceptable rhythm results. This procedure has the potential to greatly expand the indications for surgery in patients suffering from AF and deserves longer-term investigation.
Arcidi JM, Doty DB, Millar RC. 2000. The maze procedure: the LDS hospital experience. Semin Thorac Cardiovasc Surg 12:38-43.nMcCarthy PM, Gillinov AM, Castle L, et al. 2000. The Cox-maze procedure: the Cleveland Clinic experience. Semin Thorac Cardiovasc Surg 12:25-9.nRoy D, Talajic M, Dorian P, et al. 2000. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342;913-20.nSaltman AE, Rosenthal L, Francalancia NA, Lahey SJ. 2003. A completely endoscopic approach for ablation of atrial fibrillation. Heart Surgery Forum 6:2003-11333.nSchaff HV, Dearani JA, Daly RC, et al. 2000. Cox-Maze procedure for atrial fibrillation: Mayo Clinic experience. Semin Thorac Cardiovasc Surg 12:30-7.nShake JG, Larson DW, Kulick DM, et al. 2002. Transmural atrial insulating lesions using epicardially applied radiofrequency energy coupled with saline irrigation. J Invest Surg 15:101-7.nSie HT, Beukema WP, Ramdat Misier AR, et al. 2001. The radiofrequency modified maze procedure. A less invasive surgical approach to atrial fibrillation during open-heart surgery. Eur J Cardiothorac Surg 19:443-7.nSingh S, Zoble RG, Yellen L, et al. 2000. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 102:2385-90.nAtrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. 2002. A comparison of the control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-33.nAutschbach R, Onnasch JF, Falk V, et al. 2000. The Leizpig experience with robotic valve surgery. J Card Surg 15:82-7.nCox JL, Ad N, Palazzo T, et al. 2000. Current status of the maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 12:15-9.nDamiano RJ Jr, McCarthy PM, Gillinov AM, et al. 2003. Prospective multicenter clinical trial of surgical pulmonary vein isolation for the treatment of atrial fibrillation. J Am Coll Cardiol 41(suppl A):498A.nGillinov AM, Blackstone EH, McCarthy PM. 2002. Atrial fibrillation: current surgical options and their assessment. Ann Thorac Surg 74:2210-7.nKosakai Y. 2000. Treatment of atrial fibrillation using the maze procedure: the Japanese experience. Semin Thorac Cardiovasc Surg 12:44-52.nMazzitelli D, Park CH, Park KY, et al. 2002. Epicardial ablation of atrial fibrillation on the beating heart without cardiopulmonary bypass. Ann Thorac Surg 73:320-1.nThomas SP, Clout R, Deery C, et al. 1999. Microwave ablation of myocardial tissue: the effect of element design, tissue coupling, blood flow, power, and duration of exposure on lesion size. J Cardiovasc Electrophysiol. 10:72-8.nWatanabe H, Hayashi J, Sugawara M, et al. 1999. Experimental application of microwave tissue coagulation to ventricular myocardium. Ann Thorac Surg 67: 666-71.nWilliams MR, Knaut M, Berube D, Oz MC. 2002. Application of microwave energy in cardiac tissue ablation: from in vitro analyses to clinical use. Ann Thorac Surg 74:1500-5.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).